Literature DB >> 23803733

Regulation of Rb family proteins by Cdk6/Ccnd1 in growth plates.

Toshihisa Komori.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23803733      PMCID: PMC3755058          DOI: 10.4161/cc.25515

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


× No keyword cloud information.
The growth plate lacks vascular tissues and is solely composed of chondrocytes. The growth plate is composed of three layers, i.e., the resting, proliferating and hypertrophic chondrocyte layers. The chondrocytes in the resting and proliferating layers proliferate and then they uniformly maturate toward the diaphysis to become hypertrophic chondrocytes, which lose the ability to proliferate. As the growth plate lacks vasculature, apoptotic chondrocytes are not phagocytosed, and the fragmented DNA detected by TUNEL remains until they reach the bone marrow. Therefore, the growth plate is an appropriate tissue to use for evaluation of cell proliferation, differentiation, and apoptosis. We examined the effects of Cdk6 and Ccnd1 (cyclin D1) in chondrocyte proliferation, differentiation, and apoptosis. Transgenic mice overexpressing either Cdk6 or Ccnd1 in chondrocytes show no increase in the number of BrdU-positive cells, and the chondrocytes normally maturate, although CCND1 is a well-established human oncogene. In contrast, transgenic mice overexpressing both Cdk6 and Ccnd1 show dwarfism. In Cdk6/Ccnd1 double transgenic mice, chondrocyte maturation to hypertrophic chondrocytes is inhibited, and the number of BrdU-positive cells is increased, but the proliferation of chondrocytes is not enhanced, and the frequency of apoptotic chondrocytes is greatly increased. The apoptosis is rescued by p53 deletion, but chondrocyte proliferation is still not enhanced in p53–/–Cdk6/Ccnd1 double transgenic mice. Cdk6 and Ccnd1 regulate the activity of E2fs by phosphorylating Rb family proteins, Rb, p107, and p130, and trigger progression through the G0/G1 and G1/S transitions of the cell cycle. The effects of targeted deletions of Rb family genes in chondrocytes were reported by two groups.- p107-knockout mice show most apparent inhibition of chondrocyte differentiation among the knockout mice of Rb family genes. Double knockout mice of p107/p130 or p107/Rb show more severe inhibition of chondrocyte differentiation and chondrocyte proliferation is enhanced without an increase in chondrocyte apoptosis. Therefore, all of the Rb family proteins are involved in chondrocyte proliferation and differentiation, and p107 plays a major role among them. When we generated Cdk6/Ccnd1 double transgenic mice, we expected that overexpression of both Cdk6 and Ccnd1 would result in the inactivation of all Rb family proteins by their phosphorylation. However, the phenotype of Cdk6/Ccnd1 double transgenic mice was different from those of p107/p130 or p107/Rb double knockout mice. BrdU-positive cells are increased, and chondrocyte differentiation is inhibited in p107/p130 and p107/Rb double knockout mice and Cdk6/Ccnd1 double transgenic mice. However, chondrocyte proliferation is enhanced without an increase in apoptosis in p107/p130 and p107/Rb double knockout mice, whereas chondrocyte proliferation is not enhanced, and apoptotic chondrocytes are greatly increased in Cdk6/Ccnd1 double transgenic mice. In Cdk6/Ccnd1 double transgenic mice, Rb but not p107 is highly phosphorylated, and mRNA and protein levels of p107 are increased. p107 transcription is regulated by E2f, and p107 is upregulated in Rb–/– and p130–/– mouse embryonic fibroblasts.- Therefore, the phenotypic differences between p107/p130 and p107/Rb double knockout mice and Cdk6/Ccnd1 double transgenic mice could be explained by the absence or presence of p107. When Cdk6 and Ccnd1 are overexpressed, Rb, p107, and p130 should be phosphorylated, leading to the release of repressing E2fs (E2f4, 5) and activation of activating E2fs (E2f1–3), both of which enhance the transcription of E2f target genes including p107 (Fig. 1A and B). Therefore, phosphorylation of Rb, p107, and p130 enhances the transcription of p107 by E2f and unphosphorylated p107 is continuously supplied. This is the reason why unphosphorylated p107 is dominant in Cdk6/Ccnd1 double transgenic mice. Although p107 binds to repressing E2fs at the physiological condition, upregulation of p107 allows complex formation of activating E2fs with p107. Therefore, the increased amount of unphosphorylated p107 associates not only with repressing E2fs, but also with activating E2fs (Fig. 1C). As p107 plays a major role in cell cycle regulation among Rb family proteins in chondrocytes, the association of p107 with repressing and activating E2fs would affect the expression of E2f target genes. It occurs in Cdk6/Ccnd1 double transgenic mice as shown by the downregulation of cyclin E, dhfr, cdc25a, and B-Myb. Further, chondrogenic ATDC5 cells overexpressing Cdk6 and Ccnd1 also had downregulated expression of these genes, and siRNA of p107 reversed the downregulated expression of these genes. Therefore, phosphorylation of Rb, p107, and p130 upregulates p107 expression, which dysregulates E2f target gene expression leading to p53-dependent apoptosis (Fig. 1B and C). p53 deletion in addition to Rb inactivation is still not sufficient for enhancement of chondrocyte proliferation, suggesting that p107 contributes to the low incidence of chondrosarcoma as an anti-oncogenic protein, because the frequency of chondrosarcoma is much less than those of sarcomas arising in soft tissues.

Figure 1. Regulation of Rb family proteins by Cdk6/Ccnd1. (A) Rb, p107, and p130 associate with repressing E2fs (E2f4 and E2f5) which are located in the cytoplasm, the complexes translocate to the nucleus, and they bind to E2f target genes and inhibit their expression (left). Rb associates with activating E2fs (E2f1, E2f2, and E2f3) and inhibits the activity of E2fs (right). (B) Overexpression of Cdk6 and Ccnd1 phosphorylates Rb, p107, and p130, the phosphorylated Rb, p107, and p130 dissociate from the repressing E2fs, and the E2fs translocate to the cytoplasm (left). The phosphorylated Rb dissociates from the activating E2fs, and the E2fs are activated (right). In both cases, the repression of genes necessary for progression through the cell cycle is lifted. However, the expression of p107, which is regulated by E2f, is also upregulated. (C) Unphosphorylated p107 associates with repressing E2fs and suppresses the expression of E2f target genes (left). Unphosphorylated p107 also associates with activating E2fs and inhibits them (right). In both cases, the expression of E2f target genes is inhibited and the dysregulation of E2f target genes results in p53-dependent apoptosis.

Figure 1. Regulation of Rb family proteins by Cdk6/Ccnd1. (A) Rb, p107, and p130 associate with repressing E2fs (E2f4 and E2f5) which are located in the cytoplasm, the complexes translocate to the nucleus, and they bind to E2f target genes and inhibit their expression (left). Rb associates with activating E2fs (E2f1, E2f2, and E2f3) and inhibits the activity of E2fs (right). (B) Overexpression of Cdk6 and Ccnd1 phosphorylates Rb, p107, and p130, the phosphorylated Rb, p107, and p130 dissociate from the repressing E2fs, and the E2fs translocate to the cytoplasm (left). The phosphorylated Rb dissociates from the activating E2fs, and the E2fs are activated (right). In both cases, the repression of genes necessary for progression through the cell cycle is lifted. However, the expression of p107, which is regulated by E2f, is also upregulated. (C) Unphosphorylated p107 associates with repressing E2fs and suppresses the expression of E2f target genes (left). Unphosphorylated p107 also associates with activating E2fs and inhibits them (right). In both cases, the expression of E2f target genes is inhibited and the dysregulation of E2f target genes results in p53-dependent apoptosis.
  8 in total

1.  G1 cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression.

Authors:  Joaquim Calbó; Matilde Parreño; Elena Sotillo; Thomas Yong; Adela Mazo; Judit Garriga; Xavier Grana
Journal:  J Biol Chem       Date:  2002-10-24       Impact factor: 5.157

2.  p107 and p130 Coordinately regulate proliferation, Cbfa1 expression, and hypertrophic differentiation during endochondral bone development.

Authors:  Ferdinand Rossi; Helen E MacLean; Wei Yuan; Richard O Francis; Ekaterina Semenova; Carol S Lin; Henry M Kronenberg; David Cobrinik
Journal:  Dev Biol       Date:  2002-07-15       Impact factor: 3.582

3.  pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes.

Authors:  R K Hurford; D Cobrinik; M H Lee; N Dyson
Journal:  Genes Dev       Date:  1997-06-01       Impact factor: 11.361

4.  Loss of pRB and p107 disrupts cartilage development and promotes enchondroma formation.

Authors:  A S Landman; P S Danielian; J A Lees
Journal:  Oncogene       Date:  2012-11-12       Impact factor: 9.867

5.  Differential roles of two tandem E2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteins.

Authors:  L Zhu; L Zhu; E Xie; L S Chang
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

6.  Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation.

Authors:  K Ito; Z Maruyama; A Sakai; S Izumi; T Moriishi; C A Yoshida; T Miyazaki; H Komori; K Takada; H Kawaguchi; T Komori
Journal:  Oncogene       Date:  2013-04-29       Impact factor: 9.867

7.  Tandem E2F binding sites in the promoter of the p107 cell cycle regulator control p107 expression and its cellular functions.

Authors:  Deborah L Burkhart; Stacey E Wirt; Anne-Flore Zmoos; Michael S Kareta; Julien Sage
Journal:  PLoS Genet       Date:  2010-06-24       Impact factor: 5.917

8.  Shared role of the pRB-related p130 and p107 proteins in limb development.

Authors:  D Cobrinik; M H Lee; G Hannon; G Mulligan; R T Bronson; N Dyson; E Harlow; D Beach; R A Weinberg; T Jacks
Journal:  Genes Dev       Date:  1996-07-01       Impact factor: 11.361

  8 in total
  7 in total

1.  Role of microRNA-4458 in patients with non-small-cell lung cancer.

Authors:  Lidao Bao; Linlin Wang; Guomin Wei; Yuehong Wang; Gerile Wuyun; Agula Bo
Journal:  Oncol Lett       Date:  2016-09-22       Impact factor: 2.967

2.  p27 inhibits CDK6/CCND1 complex formation resulting in cell cycle arrest and inhibition of cell proliferation.

Authors:  Niannian Li; Jie Zeng; Fuze Sun; Xiaoling Tong; Gang Meng; Chunman Wu; Xin Ding; Lanlan Liu; Minjin Han; Cheng Lu; Fangyin Dai
Journal:  Cell Cycle       Date:  2018-10-24       Impact factor: 4.534

3.  H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma.

Authors:  Chao Li; Bingxi Lei; Shuaibin Huang; Meiguang Zheng; Zhenghao Liu; Zhongjun Li; Yuefei Deng
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

4.  A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.

Authors:  Nazanin Hosseinkhan; Maryam Honardoost; Zahra Emami; Sara Cheraghi; Nahid Hashemi-Madani; Mohammad E Khamseh
Journal:  Endocrine       Date:  2022-06-16       Impact factor: 3.925

Review 5.  Cell Death in Chondrocytes, Osteoblasts, and Osteocytes.

Authors:  Toshihisa Komori
Journal:  Int J Mol Sci       Date:  2016-12-06       Impact factor: 5.923

6.  BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.

Authors:  Cong Zhang; Chunrui Bo; Lunhua Guo; Pingyang Yu; Susheng Miao; Xin Gu
Journal:  World J Surg Oncol       Date:  2019-12-16       Impact factor: 2.754

7.  Antxr1, Which is a Target of Runx2, Regulates Chondrocyte Proliferation and Apoptosis.

Authors:  Qing Jiang; Xin Qin; Carolina Andrea Yoshida; Hisato Komori; Kei Yamana; Shinsuke Ohba; Hironori Hojo; Brad St Croix; Viviane K S Kawata-Matsuura; Toshihisa Komori
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.